The odyssey of marine pharmaceuticals: a current pipeline perspective

Trends in Pharmacological Sciences

Volumn 31, Issue 6, 2010, Pages 255-265

  Mayer, Alejandro M S ^a   Glaser, Keith B ^a,b   Cuevas, Carmen ^c   Jacobs, Robert S ^d   Kem, William ^e   Little, R Daniel ^d   McIntosh, J Michael ^f   Newman, David J ^g   Potts, Barbara C ^h   Shuster, Dale E ⁱ  

^a MIDWESTERN UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Research and Development Director RD PharmaMar   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h Nereus Pharmaceuticals Inc   (United States)

ⁱ EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 BENZYLIDENE 6 [(5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE] 2,5 PIPERAZINEDIONE; AMINOTRANSFERASE; ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAPECITABINE; CYTARABINE; DEHYDRODIDEMNIN B; DITERPENE; DOCETAXEL; E 7974; ELISIDEPSIN; ERIBULIN; GLYCOSIDE; HEMIASTERLIN; IDOXURIDINE; ILX 651; IRVALEC; LIVER ENZYME; MORPHINE; NATURAL PRODUCT; OMEGA CONOTOXIN MVIIA; OPIATE DERIVATIVE; PLATINUM; PM 00104; PM 02734; SOBLIDOTIN; TASIDOTIN; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; VINCA ALKALOID; ZALYPSIS; BIOLOGICAL PRODUCT; NEW DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANALGESIA; BLAST CELL CRISIS; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC PAIN; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HERPES SIMPLEX; HUMAN; KERATOCONJUNCTIVITIS; KIDNEY CANCER; LEUKEMIC MENINGITIS; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; T CELL LYMPHOMA; VASCULAR TUMOR; VIRUS KERATITIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; MARINE BIOLOGY; PROCEDURES; UNITED STATES;

ANIMALS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MARINE BIOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77953685524     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.02.005     Document Type: Review

References (99)

1. Newman D.J., et al. Therapeutic agents from the sea: biodiversity, chemo-evolutionary insight and advances to the end of Darwin's 200th year. Diving Hyperb. Med. 2009, 39:216-225.
2. Thomas X. Chemotherapy of acute leukemia in adults. Expert Opin. Pharmacother. 2009, 10:221-237.
3. Absalon M.J., et al. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin. Pharmacother. 2009, 10:57-79.
4. MARTINDALE (2009) The Complete Drug Reference (database on the internet). Cytarabine. Thomson MICROMEDEX, 2009. Available at: Accessed December 1, 2009. Micromedex Health Care, Martindale-The Complete Drug Reference (). http://www.micromedex.com/.
5. Whitley R. Neonatal herpes simplex infection. Curr. Opin. Infect. Dis. 2004, 17:243-246.
6. MARTINDALE (2009) The Complete Drug Reference (database on the internet). Vidarabine. Thomson MICROMEDEX, 2009. Available at: Accessed December 1, 2009. Micromedex Health Care, Martindale-The Complete Drug Reference (). http://www.micromedex.com/.
7. Olivera B.M. w-Conotoxin MVIIA: from marine snail venom to analgesic drug. Drugs from the Sea 2000, 75-85. Karger. N. Fusetani (Ed.).
8. Bingham J.P., et al. Drugs from slugs - past, present and future perspectives of omega-conotoxin research. Chem. Biol. Interact. 2010, 183:1-18.
9. Kerr L.M., Yoshikami D. A venom peptide with a novel presynaptic blocking action. Nature 1984, 308:282-284.
10. Miljanich G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11:3029-3040.
11. McGivern J.G. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov. Today 2006, 11:245-253.
12. Wang Y.X., et al. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000, 84:271-281.
13. Gaur S., et al. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology 1994, 33:1211-1219.
14. Staats P.S., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS - A randomized controlled trial. J. Am. Med. Assoc. 2004, 291:63-70.
15. Rauck R.L., et al. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009, 9:327-337.
16. Williams J.A., et al. Ziconotide: an update and review. Expert Opin. Pharmacother. 2008, 9:1575-1583.
17. Rinehart, K.L. et al. (1990) Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata [erratum to document cited in CA113(9):75189d]. J. Org. Chem 55, 4512-4515; Erratum: Rinehart, K.L. et al. (1991) J. Org. Chem. 56, 1676.
18. Wright A.E., et al. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J. Org. Chem. 1990, 55:4508-4512.
19. Verweij J. Soft tissue sarcoma trials: one size no longer fits all. J. Clin. Oncol. 2009, 27:3085-3087.
20. Yap T.A., et al. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
21. ® (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009, 26:322-327.
22. Zewail-Foote M., Hurley L.H. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc. 2001, 123:6485-6495.
23. Takebayashi Y., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 2001, 7:961-966.
24. Soares D.G., et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13062-13067.
25. Herrero A.B., et al. S, cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006, 66:8155-8162.
26. Erba E., et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 2001, 37:97-105.
27. Sessa C., et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer 2009, 45:1153-1161.
28. Jackson K., et al. The Halichondrins and E7389. Chem. Rev. 2009, 109:3044-3079.
29. Fodstad O., et al. Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J. Exp. Ther. Oncol. 1996, 1:119-125.
30. Towle M.J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001, 61:1013-1021.
31. Yu M.J., et al. Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. Anticancer Agents from Natural Products 2005, 241-265. CRC Press, Taylor and Francis Group, Boca Raton, Fl. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
32. Jordan M.A., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005, 4:1086-1095.
33. Okouneva T., et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008, 7:2003-2011.
34. Kuznetsov G., et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004, 64:5760-5766.
35. Goel S., et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res. 2009, 15:4207-4212.
36. Tan A.R., et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:4213-4219.
37. Vahdat L.T., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2009, 27:2954-2961.
38. Vahdat L.T., et al. Phase II study of eribulin mesylate E7389 in patients with locally advanced or metastatic breast cancer previously treated with anthracyclin, taxane, and capecitabine therapy. J. Clin. Oncol. 2008, 26(May 20 Suppl.):1084.
39. Watanabe J., et al. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Anticancer Drugs 2007, 18:905-911.
40. Lippert J.W. Vascular disrupting agents. Bioorg. Med. Chem. 2007, 15:605-615.
41. cf. (2009). http://clinicaltrials.gov/.
42. Kem W.R., et al. The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): chemical and pharmacological properties. Marine Drugs 2006, 4:255-273.
43. Kem W.R., et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol. Pharmacol. 2004, 65:56-67.
44. Buccafusco J.J., et al. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol. Sci. 2005, 26:352-360.
45. Olincy A., Stevens K.E. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem. Pharmacol. 2007, 74:1192-1201.
46. Buckingham S., et al. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol. Rev. 2009, 61:39-61.
47. Thinschmidt J.S., et al. Septal innervation regulates the function of alpha7 nicotinic receptors in CA1 hippocampal interneurons. Exp. Neurol. 2005, 195:342-352.
48. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull. 2009, 32:332-336.
49. Pavlov V.A., et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 2007, 35:1139-1144.
50. Rosas-Ballina M., et al. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol. Med. 2009, 15:195-202.
51. Yeboah M.M., et al. Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int. 2008, 74:62-69.
52. Cai B., et al. Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation. J. Cell. Mol. Med. 2008, 13:3774-3785.
53. Kitagawa H., et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003, 28:542-551.
54. Olincy A., et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 2006, 63:630-638.
55. Freedman R., et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165:1040-1047.
56. Cuadrado A., et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem. 2003, 278:241-250.
57. Garcia-Fernandez L.F., et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002, 21:7533-7544.
58. Mitsiades C.S., et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008, 68:5216-5225.
59. Le Tourneau C., et al. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des. 2007, 13:3427-3439.
60. Hamann M.T., Scheuer P.J. Kahalalide F: A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J. Am. Chem. Soc. 1993, 115:5825-5826.
61. Lopez-Macia A., et al. Synthesis and structure determination of kahalalide F (1,2). J. Am. Chem. Soc. 2001, 123:11398-11401.
62. Ling Y.H., et al. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur. J. Cancer 2009, 45:1855-1864.
63. Scott J.D., Williams R.M. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem. Rev. 2002, 102:1669-1730.
64. Leal J.F., et al. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem. Pharmacol. 2009, 78:162-170.
65. Fenical, W. et al. (1999) Halimide, a cytotoxic marine natural product, and derivatives thereof. WO/1999/048889, The Regents of the University of California, September 30, 1999.
66. Kanoh K., et al. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg. Med. Chem. Lett. 1997, 7:2847-2852.
67. Nicholson B., et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006, 17:25-31.
68. Yamazaki Y., et al. Tubulin photoaffinity labeling with biotin-tagged derivatives of potent diketopiperazine antimicrotubule agents. ChemBioChem 2008, 9:3074-3081.
69. Pilat, M.J. et al. (2009) Phase I trial of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors or lymphomas. In Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009, Denver, Colorado (CO), Vol. 50, Abstract nr. 3598.
70. Ray A., et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res. 2007, 67:3767-3776.
71. Bai R., et al. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol. Pharmacol. 2009, 75:218-226.
72. Look S.A., et al. The pseudopterosins: A new class of anti-inflammatory and analgesic diterpene pentosides from the marine sea whip Pseudopterogorgia elisabethae (Octocorallia). J. Org. Chem. 1986, 51:5140-5145.
73. Roussis V., et al. New anti-inflammatory pseudopterosins from the marine octocoral Pseudopterogorgia elisabethae. J. Org. Chem. 1990, 55:4916-4922.
74. Abatis D., et al. Atomarianones A and B: two cytotoxic meroditerpenes from the brown alga Taonia atomaria. Tetrahedron Lett. 2005, 46:8525-8529.
75. Look S.A., et al. The pseudopterosins: anti-inflammatory and analgesic natural products from the sea whip Pseudopterogorgia elisabethae. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6238-6240.
76. Ettouati W.S., Jacobs R.S. Effect of pseudopterosin A on cell division, cell cycle progression, DNA, and protein synthesis in cultured sea urchin embryos. Mol. Pharmacol. 1987, 31:500-505.
77. Mayer A.M., et al. Pharmacological characterization of the pseudopterosins: novel anti- inflammatory natural products isolated from the Caribbean soft coral, Pseudopterogorgia elisabethae. Life Sci. 1998, 62:L401-L407.
78. Moya C.E., Jacobs R.S. Pseudopterosin A inhibits phagocytosis and alters intracellular calcium turnover in a pertussis toxin sensitive site in Tetrahymena thermophila. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2006, 143:436-443.
79. Zhong W., et al. Synthesis and an evaluation of the bioactivity of the C-glycoside of pseudopterosin A methyl ether. J. Org. Chem. 2008, 73:7011-7016.
80. Cronstein B.N. Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. Purinergic Approaches in Experimental Therapeutics 1997, 285-299. Wiley-Liss. K.A. Jacobson, M.F. Jarvis (Eds.).
81. Montesinos M.C., et al. Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J. Exp. Med. 1997, 186:1615-1620.
82. IND 60606 (2000) New drug application VM301 for use in phase I/IIA clinical trials. IND 60606. filed July 12, 2000.
83. Newman D.J. The bryostatins. Anticancer Agents from Natural Products 2005, 137-150. Taylor and Francis. G.M. Cragg (Ed.).
84. Sudek S., et al. Identification of the putative bryostatin polyketide synthase gene cluster from " Candidatus Endobugula sertula" , the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J. Nat. Prod. 2007, 70:67-74.
85. Talpir R., et al. Hemiasterlin and geodiamolide TA: two new cytotoxic peptides from the marine sponge Hemiasterella minor. Tetrahedron Lett. 1994, 35:4453-4456.
86. Kowalczyk J., et al. Synthetic analogs of the marine natural product hemiasterlin: Optimization and discovery of E7974, a novel and potent antitumor agent. Proc. Am. Assoc. Cancer Res. 2005, 46. Abstract # 1212.
87. Kuznetsov G., et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol. Cancer Ther. 2009, 8:2852-2860.
88. Madajewicz S., et al. A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies. J. Clin. Oncol. 2007, 25(June 20 Suppl.):2550.
89. Zojwalla N., et al. A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies. J. Clin. Oncol. 2007, 25(June 20 Suppl.):2543.
90. Rocha Lima, C. et al. (2008) A phase I trial of E7974 administered on day 1 of a 21-day cycle in patient with advanced tumors. In Proceedings of the 2008 ASCO Gastrointestinal Cancers Symposium Abstract # 326.
91. Feling R.H., et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl. 2003, 42:355-357.
92. Fenical W., et al. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17:2175-2180.
93. Groll M., et al. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128:5136-5141.
94. Chauhan D., et al. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 2006, 95:961-965.
95. Lam K.S. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. Natural Products Chemistry for Drug Discovery 2010, 355-373. Royal Society of Chemistry. 18th edn. A.D. Buss, M.S. Butler (Eds.).
96. Sloss C.M., et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 2008, 14:5116-5123.
97. Mayer A.M., Gustafson K.R. Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds. Eur. J Cancer 2008, 44:2357-2387.
98. Mayer A.M., et al. Marine pharmacology in 2005-6: marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 2009, 1790:283-308.
99. Glaser K.B., Mayer A.M. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality. Biochem. Pharmacol. 2009, 78:440-448.